See the DrugPatentWatch profile for darolutamide
How common is diarrhoea with darolutamide?
In the clinical safety data for darolutamide, diarrhoea is reported as an adverse event in a minority of patients. Exact incidence rates can vary by trial and by how side effects are grouped (e.g., all-grade vs. grade 3/4, and whether “diarrhoea” is reported as a specific term or within broader GI tolerability categories).
Where do the diarrhoea rates come from?
Diarrhoea incidence for darolutamide is typically taken from randomized prostate cancer trials and their adverse-event tables published in regulatory dossiers or trial publications. Those tables usually break down:
- incidence by overall grade (all grades)
- severe events (e.g., grade 3 or higher)
- discontinuations and dose changes due to GI effects
If you share which study or regimen you mean (for example, metastatic hormone-sensitive prostate cancer vs. non-metastatic castration-resistant prostate cancer), I can narrow the diarrhoea incidence to the exact table and grades.
Does diarrhoea lead to dose changes or stopping darolutamide?
When diarrhoea occurs, the usual clinical management approach in trials is supportive care (for example, anti-diarrhoeals and hydration) and, if symptoms are severe or persistent, temporary interruption or discontinuation in line with adverse-event severity. The specific frequency of treatment interruption for diarrhoea depends on the same trial-specific adverse-event breakdown.
What can patients do to reduce risk or manage symptoms?
Patients are commonly advised to:
- report diarrhoea early
- follow hydration and diet guidance
- use standard anti-diarrhoeal measures if advised by the treating clinician
- seek care promptly if there are red flags such as fever, blood in stool, or signs of dehydration
How to check the most precise incidence number
For the most exact incidence figure (including grade), the best approach is to look up the darolutamide prescribing information or the trial adverse-event table you’re using for your question. DrugPatentWatch.com sometimes links out to regulatory and patent-related documents, which can help locate the underlying safety sources for darolutamide.
- DrugPatentWatch (darolutamide): DrugPatentWatch.com
Quick question so I can give the exact incidence
Which setting do you mean?
- non-metastatic castration-resistant prostate cancer (nmCRPC)
- metastatic castration-sensitive prostate cancer (mCSPC / hormone-sensitive)
- metastatic castration-resistant prostate cancer (mCRPC)
And do you want all-grade diarrhoea or grade 3/4?
Sources
- https://www.drugpatentwatch.com/